cyrilzakka/clinical-trials huggingface dataset:
Tourniquets Increase Proximal Pressure

There is an urgent clinical need to improve survival and neurologic outcomes after cardiac arrest. When a patient goes into cardiac arrest, cardiopulmonary resuscitation (CPR) with chest compressions is the current standard of care treatment to mechanically circulate blood through the patient's body. The immediate and long-term success of CPR is critically dependent on the maintenance of adequate coronary and cerebral perfusion. The investigators propose that CPR outcomes can be improved by capitalizing on the innate mechanism of vasoconstriction and preferentially routing the limited oxygenated blood to the heart and brain. The proposed solution is occlusion of extremity vasculature will increase coronary and cerebral perfusion and improve patient outcomes after cardiac arrest. Prior research has investigated the efficacy of manipulating peripheral vascular resistance with tourniquets in animal studies with improved cardiac and cerebral perfusion and survival. To prove this is an adequate solution in humans, the investigators plan to use tourniquets on the legs to occlude the peripheral vasculature in healthy humans and measure more proximal blood pressure before and after tourniquet deployment. Proof of concept of this solution will make way for development of novel devices for use during cardiac arrest and CPR to improve heart and brain perfusion and ultimately improve cardiac arrest outcomes.

The investigators will recruit 30 healthy human participants and measure their blood pressure in their arm. They will then place two commercially-available, FDA-approved tourniquets around each thigh to stop blood flow to the legs. The investigators will measure the blood pressure in the arms again. They will then release the tourniquets after blood pressure measurement. This will be repeated three times with breaks between each repetition.


Eligibility Criteria:
Inclusion Criteria:

* Healthy adults with no known chronic medical conditions between the ages of 18 and 60 years old willing and able to consent themselves.
* Subjects who are native English speakers or self-report as fluent in English.

Exclusion Criteria:

* Subjects who have a history of or are a current smoker, have a history of or current illicit drug use, have a history of or current alcohol abuse.
* Subjects who self-report as pregnant.
* Subjects who self-report diabetes, cardiac disease including hypertension requiring medication, or a history of compartment syndrome or peripheral vascular disease.
* Subjects with known chronic diseases not listed above, including but not limited to Rheumatoid Arthritis, McArdle's disease, etc.
* Subjects with elevated blood pressure (\>130/80mmHg) on the day of the study
Effect of Real-time Continuous Glucose Monitoring System in Overweight or Obese Adults With Prediabetes

In Korea, 5 million adults aged 30 years or older have diabetes. The development and expansion of Korea's economy and society, has led to dramatic chances in people's lifestyle and diet habits, and an increase in life expectancy. However, changes in lifestyle and diet habits related to the improvements of socioeconomic status may contribute to an increased diabetes burden in Korea. Therefore, it is important to prevent diabetes.

The purpose of this study was to evaluate the effects of real time-continuous glucose measurement (RT-CGM) system compared to only lifestyle modification group on blood glucose, lipid profile and diabetes prevention in prediabetic adults with overweight or obesity.

Optimising patient adherence to prescribed lifestyle interventions to achieve improved blood glucose control remains a challenge. Combined use of real-time continuous glucose monitoring (RT-CGM) systems may promote improved glycaemic control.

Thirty adult with overweight or obesity and pre-diabetes are randomised to using either RT-CGM or self monitoring of blood glucose (SMBG) for 1 week with lifestyle intervention.

After 3 month, outcomes were glycemic control (HbA1c, fasting glucose), weight, and lipid profile assessed pre- and post-intervention.

Eligibility Criteria:
Inclusion Criteria:

* ≥ BMI 23 kg/m2
* impaired fasting glucose (fasting glucose 100 to 125 mg/dL) or impaired glucose tolerance (2-h plasma glucose during oral glucose tolerance test (OGTT) 140 - 199 mg/dl) or HbA1c 5.7% to 6.4%

Exclusion Criteria:

* type 1 diabetes or type 2 diabetes or undergoing treatment for diabetes
* clinical history including malignancy
* fast history of cardiovascular disease (e.g. myocardial infarction, stroke), surgery, and trauma which may affect blood glucose within last 6 months
* taking medication (e.g. glucocorticoid, antipsychotics, anticholinergic drug etc.) which affect blood glucose
* acute infection within last 1 month
* pregnancy
VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection

Vitamin D deficiency has been linked to hypertension, autoimmune, infectious and cardiovascular diseases which are risk factors for COVID-19. Moreover, COVID-19 patients have a very high prevalence of hypovitaminosis D (Turin data). Taken together, we aim to investigate whether genetic variants in vitamin D-related genes contribute to a poor COVID-19 outcome, particularly in hypertension and CV patients, proposing thus a personalized therapeutics based on vitamin D supplementation in order to reduce the severity and deaths.

Collected data from Turin University indicate that hospitalized patients have a very high prevalence of hypovitaminosis D. Reports from China and Italy show that hypertension presents an increased risk of COVID-19-related death. Otherwise, observational studies suggest that 25(OH)D induces protection against respiratory pathogens while large-scale studies indicate that serum 25(OH)D-level is inversely correlated to hypertension prevalence. Recent published data (2020) shows that 66% of Portuguese adults present Vitamin D deficiency. HeartGenetics' genetic database with more than 8.500 Portuguese genotypes shows that the prevalence of vitamin D polymorphisms in this population is 4-fold higher than the EU average, increasing the risk of hypovitaminosis D.

Eligibility Criteria:
Inclusion Criteria:

* Adults of 18 years and above.
* COVID-19 patients admitted with mild to severe disease (admission to isolation room) or critical patients (admission to ICU).
* Available to comply with study protocol and sign informed consent.

Exclusion Criteria:

* Patients diagnosed with COVID-19 not admitted to hospital.
* Patients unable to provide informed consent.
A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

The study will look at how 2 different semaglutide versions reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different semaglutide versions. Participants will get 1 of the 2 versions of semaglutide - which version is decided by chance. One version is the one that doctors already can prescribe and the other is the new version. Participants will get the medicine as an injection under the skin of the belly with a pen-injector. The type of pen-injector is different for the 2 versions of semaglutide. Participants will receive 7 once-weekly injections in total. The study will last for about 80-106 days. Participants will have 19 study visits with the study doctor. For 2 of the visits, participants will stay in the clinic, 1 visit for 2 days and 1 night and the other visit for 4 days and 3 nights. Participants may have to stop the study if the study doctor thinks that there are risks for their health. Participants cannot take part in this study if they have any disease or disorder that the study doctor thinks is a health problem. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.


Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent.
* Body mass index (BMI) between 25.0 and 34.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
* Body weight between 65.0 and 130.0 kg (both inclusive).
* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria:

* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods.
* Any disorder which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol.
* Use of prescription medicinal products or non-prescription drugs or herbal products, except routine vitamins, topical medication, highly effective contraceptives and occasional use of paracetamol and acetylsalicylic acid (the two latter are not allowed within 24 hours before screening), within 14 days prior to the day of screening.
* Abuse or intake of alcohol, defined as any of the below:
* Known or suspected alcohol abuse within 1 year prior to the day of screening (defined as regular intake of more than an average intake of 24 g alcohol daily for men and 12 g alcohol daily for women -12 g of alcohol equals about 300 mL of beer or lager, 100 mL of wine, or 25 mL spirits)
* Positive alcohol test at screening
* Abuse or intake of drugs, defined as any of the below:
* Known or suspected drug/chemical substance abuse within 1 year prior to the day of screening
* Positive drug of abuse test at screening
Factors Associated With Residual Disease In The Central Cone

Cervical conization using the loop electrosurgical excision procedure (LEEP) is the standard treatment for patients with high-grade cervical intraepithelial neoplasia. Several studies have shown that excising a central cone reduces the rate of positive endocervical margins. The purpose of this study is to identify clinicopathological factors associated with residual disease in the central cone and to develop a predictive model to better determine which patients may require this additional procedure.

This study pretends to create a retrospective database including all patient who underwent a loop electrosurgical excision procedure by treatment for high-grade cervical intraepithelial neoplasia and create a a predictive model for top-hat resection in patients with high grade CIN

Eligibility Criteria:
Inclusion Criteria:

* patients who underwent a loop electrosurgical excision procedure (LEEP)

Exclusion Criteria:

* a diagnosis of micro-invasion or nonsquamous histology
* less than six months of follow-up
* incomplete information in their clinical charts.
Boosting The Intervention Effect of Negative Memory Through tACS Stimulation

The objectives of this study include: 1) investigating the impact of negative memory substitution on an individual's other intellectual memories (i.e., neutral memories) and the underlying neurocognitive mechanisms; 2) investigating the memory enhancement effect resulting from retrieval practice associated with memory substitution intervention along with an examination of the neurocognitive mechanisms responsible for this enhancement.

This study will adopt two memory updating strategies: retrieval practice and reactivation.

A 5-day memory updating experimental paradigm is used.

1. On the first day, the old memory A-B linkage is learned, where A represents a neutral word and B is either neutral or negative pictures (half of each, randomly scrambled).
2. On the second day, the old memory A-B association is consolidated again, and after a 15-minute break, the new memory A-C association is learned, where A is still the word A used in the old memory A-B association on the first day, and C is the new neutral and negative pictures (half of each, randomly scrambled, and with inconsistent categories of C and B in each pair of AC and AB). Immediately following this, the new memories of the A-C conjunctions are updated using both Retrieval practice and Restudy (control condition) memory strategies.
3. A-C is extracted/learned using both Retrieval practice and Restudy memory strategies on both day 3 and day 4.
4. On the fifth day, memory tests for associative memory strength, gist and detail memory, as well as emotional valence and strength are performed.

Eligibility Criteria:
Eligibility

Inclusion Criteria:

1. 14-60 years old, male or female, Han Chinese;
2. Drug-resistant epilepsy;
3. Required surgical implantation of SEEG electrodes.

Exclusion Criteria:

1. Progressive encephalopathy or progressive structural damage in the central nervous system;
2. Significant heart, liver, renal insufficiency, and other medical diseases;
3. Severe side effects from taking antiepileptic drugs at the time of enrollment and not inappropriate for SEEG;
4. Significant intellectual disability;
5. A history of alcohol and drug abuse;
6. Any contraindication to MRI.
Lenvatinib Plus PD-1 Antibody for Unresectable ICC

The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.


Eligibility Criteria:
Inclusion Criteria:

* The diagnosis of ICC
* Patients must have at least one tumor lesion that can be accurately measured according to mRECIST criteria.
* Chemotherapy resistance or patient refuse chemotherapy
* No Cirrhosis or cirrhotic status of Child-Pugh class A only
* Not amendable to surgical resection ,local ablative therapy and any other cured treatment.
* Without distant metastasis, but intrahepatic lymph node metastasis is allowed
* The following laboratory parameters:

Platelet count ≥ 50,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3

Exclusion Criteria:

* Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
* Known history of HIV
* History of organ allograft
* Known or suspected allergy to the investigational agents or any agent given in association with this trial.
* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
* Evidence of bleeding diathesis.
* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
* Known central nervous system tumors including metastatic brain disease
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis

This study evaluates the effect of cryopreserved autologous adult bone-marrow mesenchymal stromal cells (BM-MSC) in patients with active multiple sclerosis, compared to placebo.

Patients will be allocated to one of the 2 treatment arms (BM-MSC or placebo)and at month 6, the treatment will be crossed to receive the other product. The objective is to assess the safety of a single infusion BM-MSC, and to explore its efficacy in these patients.

Patients will be evaluated at month 12 and will be followed-up for a total of 3 years.

To date, there is no effective therapy to cure multiple sclerosis (MS). Immunomodulatory therapies are useful in reducing the frequency of inflammatory processes (relapses) but don't delay significantly the progression of the disease, prevent long term disability or induce the repair of damaged tissue. This proposal contemplates the use of adult autologous bone marrow mesenchymal stromal cells (BM-MSC) as an alternative therapeutic strategy to treat patients with active MS. This is a randomized, double blind, crossover clinical trial in which 8 patients with active forms of MS and moderate disability will enter the trial with the primary objective of assessing the safety and tolerability of a single intravenous infusion of BM-MSC. Secondary objectives are to assess the efficacy by gadolinium enhancing lesions though magnetic resonance imaging, neurophysiological effects and immunological effects. Once randomized, patients will undergo BM extraction and once confirmed the availability of the needed dose, they will be randomized to one of the 2 treatment arms (BM-MSC named XCEL-MC-ALPHA, or placebo). XCEL-MC-ALPHA will be cryopreserved for all patients regardless the allocated arm. At month 6, the treatment will be crossed. Patients will be evaluated at month 12 and will be followed-up for a total of 3 years.

Eligibility Criteria:
Inclusion Criteria:

* Patients between 18 and 60 years of age
* Patients with MS
* Relapsing-remitting or secondary progressive MS
* Patients to whom are not indicated or are not in a position to initiate treatment with disease-modifying drugs
* Expanded Disability Status Scale (EDDS) score \<6.5
* Nine T2 lesions at least
* Active multiple sclerosis as defined either by 1 outbreak in the last year or at least one Gadolinium-enhancing lesion in the last 6 months
* Signed informed consent form

Exclusion Criteria:

* Interferon beta or glatiramer acetate 3 months prior the screening
* Natalizumab or fingolimod in the 6 months prior the screening
* Mitoxantrone, cyclophosphamide or other immunosuppressive therapy at any time
* Has received an experimental treatment within 3 months prior the screening
* MS outbreak within the 4 weeks prior the randomization
* Serum creatinine\> 2.0 mg/dl
* Infectious disease active or uncontrolled
* Fertile patients who are not using a suitable method of contraception
* Pregnant or lactating woman
* Immunodeficiency
* Positive serology to HIV, Hepatitis B, Hepatitis C or syphilis
Chronic Kidney Disease and Cardiovascular Disease Risk Assessment

This study will investigate chronic kidney disease (CKD) and cardiovascular disease (CVD) risk factors in a sample population of Hispanics/Latinos and Caucasians in Yakima county that are rural dwelling. This investigation is intended to provide information on the impact rural geographical location and social determinants of health (SDOH) have on CKD and CVD risk factors.

Yakima County has a large hispanic farmworker population. The peak work times are between May and September. There is a growing body of research that shows the risk of agricultural workers in work environments with extreme heat.

The purpose of this pilot study is to look at incidence of non-diagnosed chronic kidney disease within Yakima County to inform future studies to examine other factors and unique bio-markers that may help in the early diagnosis of heat related injuries in agricultural workers.

Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 18 and 75

Exclusion Criteria:

* Active malignancy
* Currently pregnant
* End stage renal disease requiring dialysis
* Current active treatment for diabetes mellitus
* Current care by a nephrologist for chronic kidney disease
Reminiscence Therapy on Depression, Self Esteem, Life Satisfaction, and Loneliness of the Elderly

The primary hypothesis is, comparing with the control group, reminiscence therapy is significantly and clinically effective to improve the experiment group's depressive symptoms after six weeks therapy, and the efficacy can be maintained on the three months follow-up.

The secondary hypothesis is, comparing with the control group, reminiscence therapy significantly reduce the loneliness and increase the self-esteem and life satisfaction of the experiment group.

The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. During each weekly session, the memories recalled focused on a different theme.

Data collection will occur on screening (as for baseline or pre-test), after intervention immediately (as for post-test), and three months after the intervention (as for follow-up). And outcome measures use standardized instruments with demonstrated validity and reliability:

Geriatric Depression Scale (GDS) Rosenberg self-esteem scale (SES) Life Satisfaction Index A (LSI-A) Russell's UCLA Loneliness Scale

Eligibility Criteria:
Inclusion Criteria:

1. 60 years of age and older;
2. A score above 10 and lower than 26 on the Geriatric Depression Scale (GDS);
3. A score of 24 or higher on the Mini-Mental State Examination (MMSE);
4. Not taking anti-depressant medication or taking part in other psychotherapy when enrolling, if taking anti-depressant medication, must be stabilized on that medication for at least three months;
5. Having no problem with communication (such as, can speak fluent mandarin, or if he/she speaks a dialect, his/her dialect can be understood by most of people).

Exclusion Criteria:

1. Suicide attempt;
2. A diagnosis of cognitive impairment by DSM-Ⅳ, or mental disorders other than depression;
3. Alcohol or drug abuse;
4. Cannot grantee attending the therapy at a weekly base due to physical impairment, lack of time or unwilling etc.
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome

To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes

Cardiorenal syndrome is a clinical syndrome caused by acute or chronic injury of one of the heart and kidney resulting to acute or chronic dysfunction of the other organ. In recent years, the morbidity of cardiorenal syndrome has increased rapidly in China. Its condition is complex and difficult to treat. Due to the lack of studies specifically targeting the cardiorenal syndrome population, there is no systematic in-depth understanding of the pathogenesis and risk factors of this kind of disease. In clinic, the course of various types of cardiorenal syndrome is complex and difficult to be summarized into a specific type. Therefore, we intend to conduct a clinical systematic observation and research on such patients so as to optimize a more reasonable treatment scheme.

Eligibility Criteria:
Inclusion Criteria:

Patients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by KDIGO and ADQI expert consensus. Different syndromes were identified and classified into five subtypes. Acute CRS (type 1): acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction. Chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (CHF-CHD) leading to kidney injury and/or dysfunction. Acute reno-cardiac syndrome (type 3): acute worsening of kidney function (AKI) leading to heart injury and/or dysfunction. Chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. Secondary CRS (type 5): systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney.

Exclusion Criteria:

Pregnant or breastfeeding women; Female patients with recent birth plans; Patients who cannot follow up on medications.